aandacht en leer problemen
Conditions
Interventions
During sessie 1, participant are subjected to a mild stress task. In session
two and three, a non-invasive MRI measurement will be performed on a 7 tesla
MRI system
once after placebo and once after 60mg atomoxetine.
Sponsors
Medisch Universitair Ziekenhuis Maastricht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: In order to be eligible to participate in this study, a subject must meet all of the following criteria: * Male * No use of any psychopharmacological treatment at in the past or at time of inclusion. * No presence of a physical/medical condition that may interfere with the study * No contradiction for MRI * Age between 18 and 30 * right handedness
Exclusion criteria
Exclusion criteria: * Diagnosis of a psychiatric disorder (DSM-V) * Diagnosis of a neurological disorder * Very high (>30) or low (>18) BMI * Current recreational drug use/dependence (CIDI) * Current alcohol dependence (CIDI) * High blood pressure (>150 systolic, >100 diastolic) * Non-responders to the mild stressor in session 1
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome is the difference in fMRI activity (measurement of brain blood flow) during the attention/memory task between placebo and atomoxetine session in relation to cortisol, alpha-amylase, blood pressure, heart rate and mood after the mild stressor | — |
Secondary
| Measure | Time frame |
|---|---|
| Behavioural performance (reaction time, errors) on learning and attention tasks will be compared between placebo and atomoxetine session. | — |
Countries
Netherlands
Outcome results
None listed